CAJ | 학술논문

目的比较氨黄必利与利培酮治疗精神分裂症患者的疗效与不良反应。方法 120例符合中国精神障碍分类与诊断标准第3版精神分裂症诊断标准的患者随机分为两组，每组60例，分别给予氨黄必利和利培酮治疗8周，采用阳性与阴性症状量表（PANSS）评定疗效，治疗中出现的症状量表（TESS）评定不良反应，用世界卫生组织编制的生活质量量表（WHOQOL-100）评定生活质量。结果治疗8周后，氨黄必利组显效率73.3%，有效率90%，利培酮组显效率66.7%，总有效率86.7%，两组疗效比较差异无统计学意义（P>0.05）；两组WHOQOL-100各领域评分较治疗前均明显差异（P>0.01）；氨黄必利组不良反应发生率16.7%，利培酮组为13.3%两组差异无统计学意义（P>0.05）。结论氨黄必利与利培酮治疗精神分裂症患者的疗效相当，不良反应小，明显改善患者生活质量。
목적비교안황필리여리배동치료정신분렬증환자적료효여불량반응。방법 120례부합중국정신장애분류여진단표준제3판정신분렬증진단표준적환자수궤분위량조，매조60례，분별급여안황필리화리배동치료8주，채용양성여음성증상량표（PANSS）평정료효，치료중출현적증상량표（TESS）평정불량반응，용세계위생조직편제적생활질량량표（WHOQOL-100）평정생활질량。결과 치료8주후，안황필리조현효솔73.3%，유효솔90%，리배동조현효솔66.7%，총유효솔86.7%，량조료효비교차이무통계학의의（P>0.05）；량조WHOQOL-100각영역평분교치료전균명현차이（P>0.01）；안황필리조불량반응발생솔16.7%，리배동조위13.3%량조차이무통계학의의（P>0.05）。결론 안황필리여리배동치료정신분렬증환자적료효상당，불량반응소，명현개선환자생활질량。
Objective: To compare the efficacy and safety between amisulpride and rispeeidone in treatment of schizophrenia. Method: one hundred and twenty Patients with schizophrenia who met the schizophrenia critetion of Chinese classification of mental disorders were devided into two groups ramdomly and treated with amisulpride or riseridone for 8weeks respectively .The positive and negative scale (PANSS) and treatment Emergent side effect scale (TESS) were used to evaluate the efficacy and adverse effect respectively, the quality of life was measured by World Health Organization quality of life questionnaire (WHOQOL-100). Results:The significant efficacy rate of amisulpride group Was 73.3%and the efficacy rate was 90.0% after 8 weeks, while 66.7% and 86.7% in risperidone group . There were no statistical difference between two groups (P>0.05).The two groups showed similar improvement on quality of life. The incidence rate of adverse effect was 16.7% in amisulpride group and that was 13.3% in risperidone group, without statistical difference Between them (P>0.05). Conclusion : amisulpride and risperidone are similarly effective and safe in the treatment of schizophrenia with improving the patients, quality of life and mild side effects.